$JNJ Actelion Receives CRL from FDA for OPSUMITÂ Macitentan sNDA for the treatment of CTEPH

$JNJ Actelion Receives CRL from FDA for OPSUMIT® (Macitentan) sNDA for the treatment of CTEPH

19:38 EST 16 Jan 2019 | Odi Bruckman

$JNJ Actelion Receives CRL from FDA for OPSUMIT® (Macitentan) sNDA for the treatment of CTEPH

More From BioPortfolio on "$JNJ Actelion Receives CRL from FDA for OPSUMIT® (Macitentan) sNDA for the treatment of CTEPH"